{
    "Disease activity (follow up: 6 months; assessed with: DAS 28-ESR (Lower values â€“ > benefit) (MCID -1.17)": {
      "No of studies": ["3"],
      "Study design": "randomised trials",
      "Risk of bias": "not serious",
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "csDMARD triple therapy": ["132", "a"],
        "csDMARD monotherapy": ["379", "b"]
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.64 lower (0.95 lower to 0.33 lower)"
      },
      "Certainty": "HIGH",
      "Importance": "CRITICAL"
    },
    "Disease activity (follow up: 6 months; assessed with: ACR 20)": {
      "No of studies": ["3"],
      "Study design": "randomised trials",
      "Risk of bias": "not serious",
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "csDMARD triple therapy": ["73/132 (55.3%)" ,"a"],
        "csDMARD monotherapy": ["150/379 (39.6%)" ,"b"]
      },
      "Effect": {
        "Relative (95% CI)": "RR 1.40 (1.15 to 1.70)",
        "Absolute (95% CI)": "158 more per 1,000 (from 59 more to 277 more)"
      },
      "Certainty": "HIGH",
      "Importance": "CRITICAL"
    },
    "Disease activity (follow up: 6 months; assessed with: ACR 50)": {
      "No of studies": ["3"],
      "Study design": "randomised trials",
      "Risk of bias": "not serious",
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": "not serious",
      "Other considerations": "none",
      "No of patients": {
        "csDMARD triple therapy": ["41/132 (31.1%)", "a"],
        "csDMARD monotherapy": ["73/379 (19.3%)" ,"b"]
      },
      "Effect": {
        "Relative (95% CI)": "RR 1.61 (1.16 to 2.24)",
        "Absolute (95% CI)": "117 more per 1,000 (from 31 more to 239 more)"
      },
      "Certainty": "HIGH",
      "Importance": "CRITICAL"
    },
    "Disease activity (follow up: 6 months; assessed with: ACR 70)": {
      "No of studies": ["3"],
      "Study design": "randomised trials",
      "Risk of bias": "not serious",
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["serious", "c"],
      "Other considerations": "none",
      "No of patients": {
        "csDMARD triple therapy": ["11/132 (8.3%)" ,"a"],
        "csDMARD monotherapy": ["13/379 (3.4%)" ,"b"]
      },
      "Effect": {
        "Relative (95% CI)": "RR 2.43 (1.12 to 5.29)",
        "Absolute (95% CI)": "49 more per 1,000 (from 4 more to 147 more)"
      },
      "Certainty": "MODERATE",
      "Importance": "CRITICAL"
    }
  }